Form 4: Xenon Pharmaceuticals Director Acquires Stock Options

Director Justin D. Gover acquired stock options in Xenon Pharmaceuticals, according to a recent SEC filing.

Summary

• Justin D. Gover, a director of Xenon Pharmaceuticals Inc., filed a Form 4 with the SEC.
• The filing reports the acquisition of stock options representing the right to buy 15,542 common shares at a price of $38.16.
• These options were granted on June 5, 2024, and vest on the earlier of June 4, 2025, or the day before the company's 2025 annual meeting of shareholders.
• The options expire on June 4, 2034.
• Gover also has a power of attorney designating Sherry Aulin, Andrea DiFabio, Ilona Lo, and Nathaniel Adams to handle SEC filings on his behalf.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants, which is neither overwhelmingly positive nor negative on its own.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance beyond the vesting and expiration dates of the stock options.

Industry Context

Stock option grants are a common form of executive compensation in the pharmaceutical industry, aligning the interests of management with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and officers in publicly traded companies, particularly in the biotech and pharmaceutical sectors.
• The vesting schedule of one year is fairly typical, aligning with industry norms for incentivizing long-term performance.
• Comparing the size of the grant (15,542 shares) to similar companies would require analyzing their executive compensation packages and outstanding share counts.

Stakeholder Impact

• The stock option grant could potentially incentivize the director to act in ways that benefit shareholders, as their compensation is tied to the company's stock performance.

Key Dates